Here’s what you should know:
1. Researchers believe the treatment could be developed into a vaccine to prevent cancer in high-risk individuals.
2. Researchers published their findings in Cell Reports.
3. By reprogramming macrophages and activating natural killer cells and dendritic cells, tumor development is suppressed.
4. Researchers tested plC on mice with liver cancer at several different stages. The greatest decrease in tumor numbers and size was at one month. At three months, the impact was reduced but significant, at five months with developed tumors, there was little effect.
5. Researchers are planning future studies to evaluate how plC reacts with other agents that stop cancer growth.
More articles on gastroenterology:
GI leader to know: Dr. Thomas Ma of Penn State College
U of New Mexico to award Presidential Award of Distinction to Dr. Robert Strickland — 3 insights
Stock market week-in-review for 5 large GI companies — Nov. 6-10
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
